Hemolytic anemia
MONDO:0003664Anemia resulting from the premature destruction of the peripheral blood red cells. It may be congenital or it may be caused by infections, medications, or malignancies.
Also known as: anaemia hemolytic, anemia hemolytic, anemia, hemolytic, hemolytic anemia
188 clinical trials for this condition and its sub-types, 19 tagged with Hemolytic anemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hemolytic anemia
-
Paroxysmal nocturnal hemoglobinuria 73 trials
2 sub-types
- Paroxysmal nocturnal hemoglobinuria 1 0 trials
- Paroxysmal nocturnal hemoglobinuria 2 0 trials
-
Autoimmune hemolytic anemia 49 trials · 72 incl. sub-types
7 sub-types
- Autoimmune hemolytic anemia, warm type 29 trials
- Evans syndrome 19 trials
- Autoimmune hemolytic anemia, cold type 2 trials · 15 incl. sub-types Sub-types →
- Mixed-type autoimmune hemolytic anemia 1 trial
- Drug-induced autoimmune hemolytic anemia 0 trials
- Giant cell hepatitis with autoimmune hemolytic anemia 0 trials
- Neonatal autoimmune hemolytic anemia 0 trials
-
Familial hemolytic anemia 4 trials · 27 incl. sub-types
23 sub-types
- Congenital nonspherocytic hemolytic anemia 1 trial · 12 incl. sub-types Sub-types →
- Congenital dyserythropoietic anemia 4 trials · 5 incl. sub-types Sub-types →
- Abetalipoproteinemia 2 trials
- Cutaneous porphyria 2 trials
- Hereditary spherocytosis 2 trials Sub-types →
- Southeast Asian ovalocytosis 2 trials
- Glycogen storage disease VII 1 trial
- Glycogen storage disease due to aldolase A deficiency 1 trial
- Rh deficiency syndrome 0 trials
- X-linked congenital hemolytic anemia 0 trials
- Cryohydrocytosis 0 trials
- Dehydrated hereditary stomatocytosis 2 0 trials
- Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema 0 trials
- Elliptocytosis 1 0 trials
- Elliptocytosis 2 0 trials
- Familial pseudohyperkalemia 0 trials
- Hemolytic anemia due to diphosphoglycerate mutase deficiency 0 trials
- Hemolytic disease of fetus and newborn, RH-induced 0 trials
- Hereditary cryohydrocytosis with reduced stomatin 0 trials
- Overhydrated hereditary stomatocytosis 0 trials
- Primary CD59 deficiency 0 trials
- Renal tubular acidosis, distal, 4, with hemolytic anemia 0 trials
- Triosephosphate isomerase deficiency 0 trials
-
Hereditary stomatocytosis 1 trial · 3 incl. sub-types
7 sub-types
- Southeast Asian ovalocytosis 2 trials
- Rh deficiency syndrome 0 trials
- Cryohydrocytosis 0 trials
- Dehydrated hereditary stomatocytosis 0 trials Sub-types →
- Familial pseudohyperkalemia 0 trials
- Hereditary cryohydrocytosis with reduced stomatin 0 trials
- Overhydrated hereditary stomatocytosis 0 trials
-
Hereditary elliptocytosis 0 trials · 2 incl. sub-types
5 sub-types
- Southeast Asian ovalocytosis 2 trials
- Elliptocytosis 1 0 trials
- Elliptocytosis 2 0 trials
- Elliptocytosis 3 0 trials
- Hemolytic anemia with thermal sensitivity of red cells 0 trials
-
Non-autoimmune hemolytic anemia 1 trial
-
Heinz body anemia 0 trials
Most studied deeper sub-types
-
PNH drug iptacopan tested in Real-World setting – but study cut short
Disease control Stopped earlyThis study looked at how well the drug iptacopan works for people with paroxysmal nocturnal hemoglobinuria (PNH) when used in everyday medical practice in Russia. Only 6 adults took part, and the study was terminated early. Researchers measured whether patients' hemoglobin levels…
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Experimental immune therapy for stubborn anemia shows early promise but trial stalls
Disease control Stopped earlyThis early-phase trial tested whether low doses of interleukin-2 (IL-2), a protein that helps regulate the immune system, could help people with warm autoimmune hemolytic anemia (wAHAI) whose disease did not improve with standard steroid treatment. The study planned to give four …
Phase 1/2 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Experimental drug tested for stubborn blood disorder – but trial cut short
Disease control Stopped earlyThis early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising drug for Post-Transplant blood issues falls short in early trial
Disease control Stopped earlyThis study tested a drug called fostamatinib to help people whose blood cell counts drop after a stem cell transplant. The goal was to see if the drug could raise red blood cells or platelets without needing transfusions. The trial was stopped early after enrolling only one perso…
Phase 2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Promising drug for rare blood disorder trial halted early
Disease control Stopped earlyThis phase 3 study tested the drug parsaclisib in people with primary warm autoimmune hemolytic anemia, a condition where the immune system destroys red blood cells. The trial aimed to see if parsaclisib could improve hemoglobin levels and reduce fatigue compared to a placebo. Ho…
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
BCX9930 safety checked in PNH patients who benefited from treatment
Disease control Stopped earlyThis study looked at the long-term safety of BCX9930, an oral medication, for people with paroxysmal nocturnal hemoglobinuria (PNH) who had already benefited from the drug in a previous study. It included 28 participants and aimed to monitor side effects. The study was terminated…
Phase 2 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental drug iptacopan tested for rare blood disorders
Disease control Stopped earlyThis study tested an experimental drug called iptacopan in people with two rare blood disorders: immune thrombocytopenia (ITP) and cold agglutinin disease (CAD). The goal was to see if the drug could improve platelet counts in ITP or hemoglobin levels in CAD. The trial was termin…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug for rare blood disorder tested for long-term safety
Disease control Stopped earlyThis study tested the long-term safety of a drug called SAR445088 in people with cold agglutinin disease, a rare condition where the immune system attacks red blood cells. Only 9 participants were enrolled, and the study was terminated early. The goal was to see if the drug is sa…
Phase 1 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 16:38 UTC